Overview
- At the center of the proposal, federal premium subsidies would go directly to consumers rather than insurers to purchase coverage.
- The plan asks Congress to codify Most Favored Nation pricing deals with 16 drugmakers and to support cash‑pay discounts set to be listed on TrumpRx.gov, which is not yet active.
- It calls for restoring cost-sharing reduction payments, with a CBO estimate of $36 billion in federal savings over a decade and lower silver-plan premiums, while analysts warn some bronze and gold plan costs could rise.
- Insurers, PBMs, and providers would face new disclosure requirements on prices, margins, claim denials, and wait times, and the administration targets certain PBM fees viewed as inflating costs.
- The outline provides few timelines or dollar figures, does not extend the recently expired enhanced ACA subsidies, and arrives as the Senate continues talks on possible subsidy renewals.